Apoptosis in atherosclerosis: Pathological and pharmacological implications

Pharmacological Research

Volumn 44, Issue 2, 2001, Pages 59-71

  Guevara, Natalia V ^a   Chen, Kuang Hua ^b   Chan, Lawrence ^b  

^a UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Arteriosclerosis; Atherosclerosis; Endothelium; Macrophage atheroma dyslipidemia; Smooth muscle cells

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; PRAVASTATIN; RESVERATROL; SIMVASTATIN; TRANILAST;

ANIMAL CELL; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE DIFFERENTIATION; TISSUE REPAIR; VASCULAR SMOOTH MUSCLE;

EID: 0034917822     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0840     Document Type: Article

References (192)

1. Death in embryonic systems
2. Normal and abnormal consequences of apoptosis in the human heart. From postnatal morphogenesis to paroxysmal arrhythmias
3. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury
4. Cell death mechanisms and the immune system
5. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells
6. Apoptosis in human disease: A new skin for the old ceremony?
7. Regulation of programmed cell death or apoptosis in atherosclerosis
8. Apoptosis in atherosclerosis: Beneficial or detrimental?
9. The role of apoptosis in vascular disease
10. Apoptosis in atherosclerotic plaque. Quantitative and qualitative aspects
11. Apoptosis: Basic concepts and implications in coronary artery disease
12. Apoptosis: Basic mechanism and implications for cardiovascular disease
13. The pathogenesis of atherosclerosis: A perspective for the 1990s
14. An overview of the vascular response to injury: A tribute to the late Russell Ross
15. Lipophilic statins induce apoptosis of human vascular smooth muscle cells
16. Pro-apoptotic effect of fluvastatin on human smooth muscle cells
17. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
18. Distribution of cell replication and apoptoisi in atherosclerotic plaques of cholesterol-fed rabbits
19. Apoptosis in human atherosclerosis and restenosis
20. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability
21. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin 1β converting enzyme
22. Colocalization of CPP-32 with apoptotic cells in human atherosclerotic plaques
23. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques
24. Atherosclerosis in APOE*3-Leiden transgenic mice: From proliferative to atheromatous stage
25. Biphasic pattern of cell turnover characterizes the progression from fatty streaks to raptured human atherosclerotic plaques
26. Apoptosis in restenosis versus stable-angina atherosclerosis: Implications for the pathogenesis of restenosis
27. Inhibition of neoinitimal cell Bcl-x expression induces apoptosis and regression of vascular disease
28. Regression of atherosclerosis: Role of nitric oxide and apoptosis
29. Molecular determinants of atherosclerotic plaque vulnerability
30. 17β-estradiol inhibits apoptosis of endothelial cells
31. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?
32. Introduction of apoptosis by high pro-insulin and glucose in cultured human endothelial cells is mediated by reactive oxygen species
33. Oxidized low density lipoprotein induces apoptosis of human endothelial cells by activation of CPP-32 like proteases
34. Induction of apoptosis and of interleukine-1 beta secretion by 7-beta-hydroxycholesterol and 7-ketocholesterol: Partial inhibition of Bcl-2 overexpression
35. Angiotensin II induces apoptosis of human endothelial cells. Protective effects of nitric oxide
36. Apoptotic vascular endothelial cells become procoagulant
37. Endothelial apoptosis: Could it have a role in the pathogenesis and treatment of disease?
38. Collagen synthesis in atherosclerosis: Too much and not enough
39. Thrombin generation by apoptotic vascular smooth cells
40. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells
41. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
42. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: Relationships to vascular disease
43. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms
44. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis
45. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alfa, and interleukin-1 beta
46. Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation
47. Serum deprivation-induced apoptosis accompanied by upregulation of p53 and bax in human aortic vascular smooth muscle cells
48. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerosis plaque
49. Vascular endothelial growth factor (VEGF) and its receptors
50. Hormonal control of programmed cell death/apoptosis
51. Human connective tissue factor is expressed in advanced atherosclerotic lesions
52. Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells
53. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: An in vitro gene transfer study
54. ACE-inhibition promotes apoptosis after balloon injury of rat carotid arteries
55. Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application
56. Inhibition of NF-kappa B/Rel induces apoptosis of murine B cells
57. Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes
58. Vascular smooth muscle cells express a constitutive NF-kappa B-like activity
59. The nuclear factor-kappa B signaling pathway participates in dysregulation of vascular smooth cells in vitro and in human atherosclerosis
60. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells
61. Gamma-tocopherol decreases ox-LDL-mediated activation of nuclear factor-kappaB and apoptosis in human coronary artery endothelial cells
62. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling
63. Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and proatherosclerotic factors
64. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway
65. Modulation of vascular cell activation, function, and apoptosis: Role of antioxidants and nuclear factor-kappa B
66. Mitochondria, oxidative stress, and antioxidant defences
67. Antioxidants and apoptosis
68. Nitric oxide as a secretory product of mammalian cells
69. Nitric oxide: Physiology, pathophysiology, and pharmacology
70. Role of nitric oxide in the control of apoptosis in the microvasculature
71. Nitric oxide protects endothelial cells from tumor necrosis factor-alpha-mediated cytotoxicity: Possible involvement of cyclic GMP
72. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1-β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like protease
73. Nitric oxide inhibits Apo-1/Fas-mediated cell death
74. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite
75. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels
76. Expression of inducible nitric oxide synthase in T-lymphocytes and macrophages of cholesterol-fed rabbits
77. The contribution of inducible nitric oxide and cytomegalovirus to the stability of complex carotid plaque
78. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry
79. Apoptosis and related proteins in different stages of human atherosclerotic plaques
80. Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques
81. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells
82. Vasoactive substances regulate vascular smooth muscle cell apoptosis: Countervailing influences of nitric oxide and angiotensin II
83. Nitric oxide-mediated apoptosis in murine peritoneal macrophages
84. Age related decline in cytokine induced nitric oxide synthase activation and apoptosis in cultured endothelial cells minimal involvement of nitric oxide in the apoptosis
85. Sphingomyelinases
86. The role of sphingomyelin cycle metabolites in transduction of signals of cell proliferation, differentiation and death
87. Neutral sphingomyelinase
88. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms
89. Sphingolipids in atherosclerosis and vascular biology
90. Neutral sphingomyelinase: Past, present and future
91. Modulating apoptosis: Current applications and prospects for future drug development
92. Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and independent pathways
93. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques
94. Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis
95. Characterization of apoptotic macrophages in atheromatous tissue of humans and heritable hyperlipidemic rabbits
96. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo
97. Topographical association between the cyclin-dependent kinases inhibitor p21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue
98. Co-expression of p53 and MDM2 in human atherosclerosis: Implications for the regulation of cellularity of atherosclerotic lesions
99. Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis
100. Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells. Potential role of p53 in regulation of vascular smooth muscle cell growth
101. The regulation of vascular smooth muscle cell apoptosis
102. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax
103. Apoptosis meets signal transduction: Elimination of a BAD infulence
104. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death
105. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
106. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
107. Myc signalling via ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
108. Expression of human cytomegalovirus immediate early genes increases rat smooth muscle cell proliferation
109. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
110. The association of infection and coronary artery disease: An update
111. Cytomegalovirus genome and the immediate-early antigen in cells of different layers of human aorta
112. Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53
113. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells
114. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate
115. Regulation of p53 downstream genes
116. The Fas death factor
117. Fas ligand-induced apoptosis
118. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells
119. The role of Fas/Apo 1 and apoptosis in the development of human atherosclerotic lesions
120. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes
121. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis
122. Involvement of an ICE-like protease in Fas-mediated apoptosis
123. Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis. Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis
124. Chemical composition and physical state of lipid deposits in atherosclerosis
125. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis
126. Free cholesterol loading of macrophages induces apoptosis involving the Fas pathway
127. Apoptosis in the vasculature: Mechanisms and functional importance
128. Neurohormonal modulation in cardiovascular disease
129. Vascular gene transfer for the treatment of restenosis and atherosclerosis
130. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
131. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response
132. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumor
133. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system
134. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
135. In vitro evidence that metabolic corporation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
136. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy
137. Selective elimination of recombinant genes in vivo with a retroviral vector
138. Beneficial effects of statins in coronary artery disease - Beyond lowering cholesterol
139. Effect of statin therapy on restenosis after coronary stent implantation
140. Cholesterol and recurrent events trail investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
141. Pleiotropic effects of statins
142. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
143. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
144. Statins do more than lower cholesterol
145. Modulation of the mevalonate pathway: Potential mechanisms of vascular protection independent of cholesterol reduction
146. New insights into the pharmacodynamic and pharmacokinetic properties of statins
147. Pleiotropic effects of statins in atherosclerosis and diabetes
148. Non-lipid-lowering effects of statins on atherosclerosis
149. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability
150. HMG CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
151. Anti-atherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation
152. The pathogenesis of atherosclerosis
153. Cytokines and growth regulatory molecules in atherosclerosis
154. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733)
155. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis
156. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro
157. Lipophilic statins induce apoptosis of human vascular smooth muscle cells
158. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells
159. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
160. Lovastatin induces p21WAF1/CIPI in human vascular smooth muscle cells: Influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition
161. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease
162. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
163. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
164. Signal transduction pathways regulated by mitogen-activated extracellular response kinase kinase kinase induce cell death
165. Apoptosis: Basic mechanisms and implications for cardiovascular disease
166. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells
167. Regression of atherosclerosis: Role of nitric oxide and apoptosis
168. Tranilast in the therapy of coronary artery disease
169. Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors
170. Modulation of human monocyte activities by tranilast, SB 252218, a compound-demonstrating efficacy in restenosis
171. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II
172. The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial
173. Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart
174. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells
175. Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT)
176. Tranilast restores cytokine-induced nitric oxide production against platelet-derived growth factor in vascular smooth muscle cells
177. Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1
178. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells
179. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells
180. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells
181. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway
182. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes
183. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells
184. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2
185. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine
186. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?
187. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity
188. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation
189. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase
190. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells
191. Resveratrol as a new type of DNA-cleaving agent
192. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs